University of Sydney, NSW, Australia.
Aust N Z J Psychiatry. 2010 Dec;44(12):1089-96. doi: 10.3109/00048674.2010.512864.
To assess the beliefs of pharmacists about the helpfulness of interventions for schizophrenia and depression.
A survey instrument containing a measure of mental health literacy was mailed to a random sample of 2000 pharmacists registered with the Pharmacy Board of New South Wales in November 2009. Vignettes of a person with either depression or psychosis were presented, followed by questions related to the recognition of the disorder, the helpfulness of various interventions, prognosis with and without professional help, the person's long-term functioning in various social roles and the likelihood of the person being discriminated against.
A total of 391 responses were received (response rate 19.5%). The majority of pharmacists correctly identified depression (92%) with fewer recognizing schizophrenia (79%). Pharmacists rated medicine use highly for both schizophrenia and depression but were also positive about the use of psychological therapies and lifestyle interventions. Pharmacists had negative views about admission to a psychiatric ward and the use of electroconvulsive therapy (ECT). However, younger pharmacists had significantly more positive views on the use of ECT (p = 0.001). The majority of pharmacists (74%) thought discrimination by the community was highly likely and rated long-term prognosis as poor without appropriate professional help. Their views on the likelihood of specific negative outcomes were mixed, with many pharmacists not recognizing the risk of suicide in schizophrenia and depression. However, both female (p = 0.002) and younger pharmacists (p < 0.001) were significantly more inclined to rate the likelihood of suicide as more likely in a person with schizophrenia or depression.
The majority of pharmacists had a high degree of mental health literacy as indicated by the correct identification of, and support for evidence-based interventions for mental illnesses. Pharmacists should be aware that their attitudes and stigma towards mental illness may impact on the patient care they provide.
评估药剂师对精神分裂症和抑郁症干预措施有效性的看法。
于 2009 年 11 月,向新南威尔士州药剂师委员会注册的 2000 名药剂师随机抽取样本,邮寄了一份包含心理健康知识量表的调查问卷。调查采用病例对照研究,向药剂师展示一位抑郁症或精神分裂症患者的病例,随后询问他们对疾病的识别、各种干预措施的有效性、有无专业帮助的预后、患者在各种社会角色中的长期功能以及患者被歧视的可能性等问题。
共收到 391 份回复(回复率 19.5%)。大多数药剂师正确识别了抑郁症(92%),而识别精神分裂症的比例较低(79%)。药剂师对精神分裂症和抑郁症的药物治疗都给予高度评价,但对心理治疗和生活方式干预也持积极态度。药剂师对住院治疗和电休克疗法(ECT)的看法较为负面。然而,年轻的药剂师对 ECT 的使用有更积极的看法(p = 0.001)。大多数药剂师(74%)认为社区的歧视可能性很高,如果没有适当的专业帮助,他们对预后的评价较差。他们对特定负面结果的可能性的看法不一,许多药剂师没有意识到精神分裂症和抑郁症患者自杀的风险。然而,女性(p = 0.002)和年轻的药剂师(p < 0.001)更倾向于认为精神分裂症或抑郁症患者自杀的可能性更大。
大多数药剂师具有较高的心理健康素养,表现在他们能够正确识别精神疾病,并支持基于证据的干预措施。药剂师应该意识到他们对精神疾病的态度和污名可能会影响他们为患者提供的护理。